Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Loading
Home›
Research›
Investment Firms›
Decheng Capital
AddedFeb 13, 2024
UpdatedJun 28, 2026
Decheng Capital

Decheng Capital

Operating

Decheng Capital: A leading venture capital firm, investing in early and growth-stage healthcare and life sciences.

Location
Menlo Park, CA, US
Founded
2012
Firm
Compare
Portfolio
Employees
Website

Investments

Nalu Medical
Nalu Medical

Total Raised

$180.9M

Rounds

3

Series E$65MJanuary 2024
Series Unknown$104MFebruary 2022
Adela
Adela

Total Raised

$108M

Rounds

2

Series A$48MSeptember 2023
Series A$60MJune 2021
Cellares
Cellares

Total Raised

$355M

Rounds

3

Series C$255MAugust 2023
Series B$82MMay 2021
Upstream Bio
Upstream Bio

Total Raised

$408M

Rounds

4

Series B$200MJune 2023
Series A$200MJune 2022
VintaBio
VintaBio

Total Raised

$64M

Rounds

1

Series Unknown$64MApril 2023
LevitasBio
LevitasBio

Total Raised

$61M

Rounds

3

Series C$35MOctober 2022
Series B$18MJanuary 2021
Watchmaker Genomics
Watchmaker Genomics

Total Raised

$48.3M

Rounds

2

Series A$40MJune 2022
Mirvie
Mirvie

Total Raised

$70.4M

Rounds

4

Series B$45MMay 2022
Solve Therapeutics
Solve Therapeutics

Total Raised

$126M

Rounds

1

Series A$126MJanuary 2022
Immpact Bio
Immpact Bio

Total Raised

$129M

Rounds

2

Series B$111MJanuary 2022
Alpine Immune Sciences
Alpine Immune Sciences
Acquired

Total Raised

$475.3M

Rounds

8

Post Ipo Equity$91MSeptember 2021
Mammoth Biosciences
Mammoth Biosciences

Total Raised

$264.5M

Rounds

7

Series D$150MSeptember 2021
Series C$45MNovember 2020
Shape Therapeutics
Shape Therapeutics

Total Raised

$147.5M

Rounds

2

Series B$112MJuly 2021
Xtremity
Xtremity

Total Raised

$15.8M

Rounds

2

Series Unknown$7.7MJune 2021
PackGene Biotech
PackGene Biotech

Total Raised

$100M

Rounds

6

Series CApril 2021
Series BOctober 2020
Neurelis
Neurelis
Public

Total Raised

$206.1M

Rounds

9

Series D$114MMarch 2021
Equillium
Equillium
Public

Total Raised

$85M

Rounds

5

Post Ipo Equity$30MFebruary 2021
Encodia
Encodia

Total Raised

$75M

Rounds

1

Series C$75MJanuary 2021